pleural neoplasms

Summary

Summary: Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.

Top Publications

  1. ncbi Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    Nicholas J Vogelzang
    University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA
    J Clin Oncol 21:2636-44. 2003
  2. ncbi Advances in malignant mesothelioma
    Bruce W S Robinson
    School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia
    N Engl J Med 353:1591-603. 2005
  3. ncbi Malignant mesothelioma
    Bruce W S Robinson
    Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Australia
    Lancet 366:397-408. 2005
  4. pmc The European mesothelioma epidemic
    J Peto
    Section of Epidemiology, The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 79:666-72. 1999
  5. ncbi Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute
    Jan P van Meerbeeck
    Thoracic Oncology Unit, University Hospital 7K12IE, De Pintelaan 185, B 9000 Ghent, Belgium
    J Clin Oncol 23:6881-9. 2005
  6. pmc Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
    Tom Treasure
    Department of Mathematics, Clinical Operational Research Unit, University College London, London, UK
    Lancet Oncol 12:763-72. 2011
  7. ncbi Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
    A Scherpereel
    Dept of Pulmonary and Thoracic Oncology, Hopital Calmette, CHRU of Lille, 59037 Lille Cedex, France
    Eur Respir J 35:479-95. 2010
  8. ncbi Mesothelin-family proteins and diagnosis of mesothelioma
    Bruce W S Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Western Australia, Perth, Australia
    Lancet 362:1612-6. 2003
  9. ncbi Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models
    Alessandro Marinaccio
    Epidemiology Unit, Occupational Medicine Department, National Institute for Occupational Safety and Prevention, Rome, Italy
    Int J Cancer 115:142-7. 2005
  10. ncbi Asbestos exposure, pleural mesothelioma, and serum osteopontin levels
    Harvey I Pass
    Department of Surgery, Wayne State University, Karmanos Cancer Institute, John A Dingell Veterans Hospital, Detroit, Mich, USA
    N Engl J Med 353:1564-73. 2005

Research Grants

  1. Diagnosis and prognosis of lung cancer using gene ratios
    GAVIN GORDON; Fiscal Year: 2004
  2. COMPUTER AIDED DIAGNOSIS IN CT OF THE THORAX
    Samuel Armato; Fiscal Year: 2004
  3. Standard Database for CT Lung Images
    Samuel Armato; Fiscal Year: 2006
  4. Computerized Analysis of Mesothelioma on CT Scans
    Samuel Armato; Fiscal Year: 2009
  5. CANCER AND LEUKEMIA GROUP B
    David Sugarbaker; Fiscal Year: 2002
  6. Gene Ratios for Lung Cancer Detection and Prognosis
    Raphael Bueno; Fiscal Year: 2004
  7. Gene Ratio Based Prognosis in Mesothelioma
    Raphael Bueno; Fiscal Year: 2007
  8. Role of Cell Mediators in Asbestos-SV40 Carcinogenesis
    Michele Carbone; Fiscal Year: 2009
  9. A Decision Aid for Cancer-Surviving Adolescents
    Patricia Hollen; Fiscal Year: 2008
  10. SV40 sequences in human tumors: analysis & biologic*
    Michele Carbone; Fiscal Year: 2006

Detail Information

Publications293 found, 100 shown here

  1. ncbi Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    Nicholas J Vogelzang
    University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA
    J Clin Oncol 21:2636-44. 2003
    ..We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone...
  2. ncbi Advances in malignant mesothelioma
    Bruce W S Robinson
    School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia
    N Engl J Med 353:1591-603. 2005
  3. ncbi Malignant mesothelioma
    Bruce W S Robinson
    Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Australia
    Lancet 366:397-408. 2005
    ..Gene therapy and immunotherapy are used on an experimental basis only. Patterns identified from microarray studies could be useful for diagnosis as well as prognostication...
  4. pmc The European mesothelioma epidemic
    J Peto
    Section of Epidemiology, The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 79:666-72. 1999
    ..The model was tested by comparing observed and predicted numbers of deaths for the period 1990-94. The ratio of mesothelioma to recorded pleural cancer mortality has been 1.6:1 in Britain but was assumed to be 1:1 in other countries...
  5. ncbi Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute
    Jan P van Meerbeeck
    Thoracic Oncology Unit, University Hospital 7K12IE, De Pintelaan 185, B 9000 Ghent, Belgium
    J Clin Oncol 23:6881-9. 2005
    ....
  6. pmc Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
    Tom Treasure
    Department of Mathematics, Clinical Operational Research Unit, University College London, London, UK
    Lancet Oncol 12:763-72. 2011
    ..We aimed to assess the clinical outcomes of patients who were randomly assigned to EPP or no EPP in the context of trimodal therapy in the Mesothelioma and Radical Surgery (MARS) feasibility study...
  7. ncbi Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
    A Scherpereel
    Dept of Pulmonary and Thoracic Oncology, Hopital Calmette, CHRU of Lille, 59037 Lille Cedex, France
    Eur Respir J 35:479-95. 2010
    ..Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre...
  8. ncbi Mesothelin-family proteins and diagnosis of mesothelioma
    Bruce W S Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Western Australia, Perth, Australia
    Lancet 362:1612-6. 2003
    ..Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals...
  9. ncbi Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models
    Alessandro Marinaccio
    Epidemiology Unit, Occupational Medicine Department, National Institute for Occupational Safety and Prevention, Rome, Italy
    Int J Cancer 115:142-7. 2005
    ..The findings predict a peak with about 800 mesothelioma annual deaths in the period 2012-2024. Results estimated using age-period-cohort models were similar to those obtained from the asbestos consumption model...
  10. ncbi Asbestos exposure, pleural mesothelioma, and serum osteopontin levels
    Harvey I Pass
    Department of Surgery, Wayne State University, Karmanos Cancer Institute, John A Dingell Veterans Hospital, Detroit, Mich, USA
    N Engl J Med 353:1564-73. 2005
    ....
  11. ncbi Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment
    Bogdan Dragos Grigoriu
    Institut National de la Sante et de la Recherche Medicale INSERM U774, Institut Pasteur de Lille, Lille, France
    Clin Cancer Res 13:2928-35. 2007
    ..We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects...
  12. ncbi Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma
    Arnaud Scherpereel
    INSERM Unit 774, Institut Pasteur de Lille, 59037 Lille Cedex, France
    Am J Respir Crit Care Med 173:1155-60. 2006
    ..Diagnosis of malignant pleural mesothelioma is a challenging issue. Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet...
  13. ncbi Advances in the biology of malignant pleural mesothelioma
    P A Zucali
    Department of Medical Oncology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Cancer Treat Rev 37:543-58. 2011
    ..This paper reviews advances in the molecular biology of malignant pleural mesothelioma in terms of pathogenesis, the major molecular pathways and the associated therapeutic strategies, and the roles of biomarkers...
  14. ncbi Inflammation-based prognostic indices in malignant pleural mesothelioma
    David James Pinato
    Department of Investigative Sciences, Imperial College London, Hammersmith Campus, London, UK
    J Thorac Oncol 7:587-94. 2012
    ..Our aim was to compare the prognostic performance of three inflammation-based biomarkers in predicting overall survival (OS) in MPM...
  15. ncbi Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma
    Noriko Hirayama
    Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1 1 Mukogawa cho, Nishinomiya, Hyogo 663 8501, Japan
    Respir Med 105:137-42. 2011
    ..Here, we investigated the pleural effusion VEGF levels in patients with MPM and compared them to those of a population with a non-malignant pleuritis or lung cancer involving malignant pleural effusion...
  16. ncbi Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations
    Ottavio Rena
    Thoracic Surgery Unit, University of Eastern Piedmont, Azienda Ospedaliero Universitaria Maggiore della Carita, C so Mazzini, 18, Novara, Italy
    J Surg Oncol 104:701-5. 2011
    ..To evaluate epidermal growth factor receptor (EGFR) phenotypic expression and related gene status in malignant pleural mesothelioma (MPM) and to correlate the results with patients' prognosis...
  17. pmc A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma
    Daniel H Sterman
    Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, 19104 4283, USA
    Am J Respir Crit Care Med 184:1395-9. 2011
    ..Clinical trial registered with www.clinicaltrials.gov (NCT 01212367)...
  18. ncbi Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma
    Amie Y Lee
    Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Oncogene 23:6672-6. 2004
    ..Our results suggest that methylation silencing of SFRPs may be one of the important mechanisms of aberrant Wnt signaling activation in MM...
  19. ncbi Molecular changes in mesothelioma with an impact on prognosis and treatment
    Didier Jean
    INSERM, U, Universite Paris Descartes, UMR S, Paris, France
    Arch Pathol Lab Med 136:277-93. 2012
    ..In recent decades, research on malignant pleural mesothelioma (MPM) has been developed to improve patients' outcomes by increasing the level of confidence in MPM diagnosis and prognosis...
  20. ncbi Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan
    Shuko Nojiri
    Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Jpn J Clin Oncol 41:32-9. 2011
    ..The objective in our study was to examine baseline and other characteristics associated with survival in patients with malignant pleural mesothelioma in Japan...
  21. pmc Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
    Hedy L Kindler
    University of Chicago ComprehensiveCancer Center, Chicago, IL, USA
    J Clin Oncol 30:2509-15. 2012
    ..We added the anti-VEGF antibody bevacizumab to gemcitabine/cisplatin in a multicenter, double-blind, placebo-controlled randomized phase II trial in patients with previously untreated, unresectable MM...
  22. ncbi Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
    W Weder
    Department of Thoracic Surgery, University Hospital Zurich, Switzerland
    Ann Oncol 18:1196-202. 2007
    ..The aim of this multicenter trial was to prospectively evaluate neo-adjuvant chemotherapy followed by extrapleural pneumonectomy (EPP) and radiotherapy, including quality of life as outcome...
  23. ncbi PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma
    Anna R Laury
    Department of Pathology Section, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 34:627-35. 2010
    ..The presence of weak staining for PAX8 in the 3 "noninvasive" mesotheliomas questions the use for PAX8 in this differential diagnosis. On the basis of this study, h-caldesmon is not a useful marker for mesothelioma...
  24. ncbi CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
    Noriyuki Yamada
    First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita ku, Sapporo, 060 8638, Japan
    Cancer Immunol Immunother 59:1543-9. 2010
    ..Thus, the stimulation of CD8(+) lymphocytes might be an efficacious immunotherapy for MPM patients...
  25. ncbi Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)
    S Cedres
    Medical Oncology Service Vall d Hebron University Hospital, Barcelona, Spain
    Lung Cancer 77:192-8. 2012
    ..Malignant pleural mesothelioma (MPM) is a highly aggressive neoplasm with elevated AKT/mTOR activity. We aimed to identify the expression and phosphorylation status of PTEN, PI3K and downstream signaling in MPM...
  26. pmc hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma
    Harvey I Pass
    Thoracic Surgery, NYU Langone Medical Center, New York, New York 10016, USA
    Cancer Res 70:1916-24. 2010
    ..A single miR has the potential to be a prognostic biomarker in mesothelioma, and validation of these findings as well as investigation of its downstream targets may give insight for potential therapies in the future...
  27. ncbi AXL regulates mesothelioma proliferation and invasiveness
    W B Ou
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Oncogene 30:1643-52. 2011
    ..AXL inhibition suppressed mesothelioma anchorage-independent growth, with reduction in colony numbers and size. These studies suggest that AXL inhibitors warrant clinical evaluation in mesothelioma...
  28. ncbi Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy
    Mir Alireza Hoda
    Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria
    J Thorac Oncol 6:852-63. 2011
    ..Here, we investigated the feasibility of mammalian target of rapamycin (mTOR) inhibition by temsirolimus as an antimesothelioma strategy...
  29. ncbi The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
    Matthew Bott
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 43:668-72. 2011
    ..These findings implicate transcriptional deregulation in the pathogenesis of MPM...
  30. ncbi Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
    J E Herndon
    CALGB Statistical Center, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Chest 113:723-31. 1998
    ..To examine the individual and joint effect of various pretreatment clinical characteristics on the survival of patients with mesothelioma treated by the Cancer and Leukemia Group B (CALGB)...
  31. ncbi Solitary fibrous tumors of the pleura: surgical outcome and clinical course
    Sook Hwan Sung
    Department of Thoracic Surgery, Seoul National University, Seoul, South Korea
    Ann Thorac Surg 79:303-7. 2005
    ..The aim of this study was to define more precisely the surgical outcome and clinical course of solitary fibrous tumors of the pleura...
  32. ncbi A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma
    Jonathan E Dowell
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Lung Cancer 77:567-71. 2012
    ..We evaluated the addition of bevacizumab to cisplatin and pemetrexed as first-line treatment in patients with advanced, unresectable MM...
  33. ncbi Initial analysis of the international association for the study of lung cancer mesothelioma database
    Valerie W Rusch
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1631-9. 2012
    ..To plan revisions of this system, the International Association for the Study of Lung Cancer Staging Committee developed an international database. Initial analyses focus on patients managed surgically...
  34. pmc Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis
    Kevin Hollevoet
    Ghent University Hospital, Ghent, Belgium
    J Clin Oncol 30:1541-9. 2012
    ..To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis...
  35. ncbi Malignant pleural mesothelioma: current treatments and emerging drugs
    Carmen Belli
    San Raffaele Scientific Institute, Oncology Department, 60 Olgettina Street, Milan 20132, Italy
    Expert Opin Emerg Drugs 14:423-37. 2009
    ..Better understanding of molecular pathways involved in MPM has enabled inclusion of new drugs targeted against pathways responsible for proliferation, cell survival and angiogenesis...
  36. ncbi Increased but low incidence and poor survival of malignant mesothelioma in the southeastern part of The Netherlands since 1970: a population-based study
    M L Janssen-Heijnen
    Comprehensive Cancer Centre South, Eindhoven, The Netherlands
    Eur J Cancer Prev 8:311-4. 1999
    ..In view of presumed limited exposure to asbestos and small geographical variation, the incidence of mesothelioma in the southeastern part of The Netherlands will probably remain low, despite an increase in the past decades...
  37. ncbi Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
    Francesco Barone-Adesi
    Unit of Cancer Epidemiology, CeRMS and Center for Oncologic Prevention Piemonte, University of Turin, Turin, Italy
    Int J Cancer 123:912-6. 2008
    ..The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs...
  38. ncbi Malignant pleural mesothelioma: a population-based study of survival
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Thorac Oncol 5:1841-8. 2010
    ..This study characterizes the overall survival (OS) and variables affecting OS in patients with malignant pleural mesothelioma...
  39. pmc The evolution of multimodality therapy for malignant pleural mesothelioma
    Marjorie G Zauderer
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Treat Options Oncol 12:163-72. 2011
    ..Clearly, MPM requires a multidisciplinary approach and, due to the myriad of open questions, much effort continues to focus on identifying the optimal combination of surgery, chemotherapy, and radiation...
  40. pmc A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
    A K Nowak
    Department of Medical Oncology, Sir Charles Gairdner Hospital, Verdun Street, Nedlands, WA 6009 Australia
    Br J Cancer 87:491-6. 2002
    ..Investigation of alternative scheduling is needed to decrease haematological toxicity and increase the relative dose intensity of gemcitabine whilst maintaining response rate and quality of life...
  41. pmc Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy
    Daniela Ferrante
    Unit of Medical Statistics and Cancer Epidemiology, CPO Piemonte and University of Eastern Piedmont, Novara, Italy
    Environ Health Perspect 115:1401-5. 2007
    ..Although the hazard is established, the magnitude of the risk is uncertain, and it is unclear whether risk is also increased for other cancers. Few cohort studies have been reported...
  42. ncbi Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates
    J Daubriac
    INSERM, U674, Fondation Jean Dausset CEPH, IFR105, Paris, France
    Cell Death Differ 16:1146-55. 2009
    ..Finally, our findings show that impairment of cell aggregation activates SAPK/JNK and Bim and induces anoikis. Our results underline the importance of intercellular contacts in the anoikis resistance of MPM cells...
  43. ncbi Update on malignant pleural mesothelioma
    Nicholas Paul Campbell
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, Illinois 60647, USA
    Semin Respir Crit Care Med 32:102-10. 2011
    ..Key questions about maintenance therapy and the optimal regimens for elderly and frail patients remain to be answered. Although few other cytotoxic drugs have activity, a surprising number of novel agents are being investigated...
  44. ncbi Management of malignant pleural mesothelioma
    Sophie D West
    Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, UK
    Clin Chest Med 27:335-54. 2006
    ..This article summarizes important advances in the management of mesothelioma, especially diagnostic and therapeutic aspects...
  45. ncbi Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
    Koji Kawaguchi
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya, Japan
    Carcinogenesis 30:1097-105. 2009
    ....
  46. ncbi Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
    Gavin J Gordon
    The Thoracic Surgery Oncology Laboratory and the Division of Thoracic Surgery, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA
    Cancer Chemother Pharmacol 61:549-58. 2008
    ..Bortezomib may improve outcome in MPM patients alone or in combination with standard chemotherapy but the order of administration is likely to be important. This study justifies further evaluation of bortezomib in MPM...
  47. ncbi Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development
    Dean A Fennell
    Department of Medical Oncology, Lung Cancer and Mesothelioma Research Group, St Bartholomew s Hospital, West Smithfield, London, UK
    Lancet Oncol 5:354-62. 2004
    ..This review discusses recent developments in apoptosis biology that are specific to mesothelioma and the therapeutic implications for this aggressive cancer...
  48. ncbi Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor
    Emiko Nakataki
    Department of Internal Medicine and Molecular Therapeutics, University of Tokushima Graduate School, 3 18 15 Kuramoto cho, Tokushima 770 8503, Japan
    Cancer Sci 97:183-91. 2006
    ..Our patient-like orthotopic model using EHMES-10 cells overexpressing VEGF and its receptor may be useful for examining the molecular pathogenesis of MPM and may contribute to the development of novel treatment strategies for MPM...
  49. ncbi Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy
    J Clin Oncol 24:1443-8. 2006
    ..This multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with malignant pleural mesothelioma (MPM)...
  50. ncbi Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions
    Harvey I Pass
    Department of Cardiothoracic Surgery, Division of Thoracic Surgery, New York University School of Medicine, New York, New York 10016, USA
    Ann Thorac Surg 85:265-72; discussion 272. 2008
    ..Soluble mesothelin-related peptide (SMRP) is a potential marker for malignant pleural mesothelioma (MPM), which may be useful for screening high-risk asbestos-exposed individuals...
  51. pmc Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma
    Lee M Krug
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:3007-13. 2009
    ....
  52. ncbi Advances in the systemic therapy of malignant pleural mesothelioma
    Dean A Fennell
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Liburn Road, Belfast BT9 7BL, Northern Ireland, UK
    Nat Clin Pract Oncol 5:136-47. 2008
    ..Coupled with high-quality translational research, such developments have real potential to improve the outlook of patients at a time of increasing incidence...
  53. ncbi Solitary fibrous tumor of the pleura
    Lary A Robinson
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:264-9. 2006
    ..Only about 800 cases have been reported in the medical literature. The tumor appears to be unrelated to malignant pleural mesothelioma, the most common primary tumor of the pleura...
  54. ncbi The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure
    J T Hodgson
    Epidemiology and Medical Statistics Unit, Health and Safety Executive, Magdalen House, Stanley Precinct, L20 3QZ, Bootle, UK
    Ann Occup Hyg 44:565-601. 2000
    ..Based on these considerations, and a discussion fo the associated uncertainties, a series of quantified risk summary statements for different elvels of cumulative exposure are presented...
  55. ncbi Predicting survival in malignant mesothelioma
    A W Musk
    Schools of Population Health and Medicine and Pharmacology, University of Western Australia, Western Australia, Australia
    Eur Respir J 38:1420-4. 2011
    ..With increasing resources and treatment costs for MM over the past 40 yrs, there have been modest improvements in survival but no complete remissions...
  56. pmc Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network
    Qi Li
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Am J Pathol 179:1483-93. 2011
    ..These findings indicate that MPM instigates tumor-associated fibroblasts, promoting tumor progression via a malignant cytokine network. Regulation of this cytokine network may be therapeutically useful for controlling MPM...
  57. ncbi Validation of tissue microarray technology in malignant pleural mesothelioma
    Steven C H Kao
    Asbestos Diseases Research Institute, Bernie Banton Centre, Concord, Australia
    Pathology 43:128-32. 2011
    ..Given the intralesional heterogeneity of MPM, it is questionable if TMAs can adequately represent MPMs. We here investigate the validity of TMAs for MPM...
  58. pmc In vitro and in vivo characterization of highly purified human mesothelioma derived cells
    Alice Melotti
    Department of Oncology, Biology and Genetics, University of Genova, Genova, Italy
    BMC Cancer 10:54. 2010
    ..Our work was aimed to establish from fresh human pleural mesothelioma samples cell cultures maintaining tumorigenic properties...
  59. ncbi Successful extirpation of thoracic pleural lipoma by single-port thoracoscopic surgery
    Soichi Oka
    Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
    Asian J Surg 34:140-2. 2011
    ..The resected tumor was a pedunculated pleural mass, yellowish in color, and pathological diagnosis confirmed a lipoma. We describe the first known successful treatment by single-port VATS...
  60. ncbi Multimodality strategies in malignant pleural mesothelioma
    Walter Weder
    Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
    Semin Thorac Cardiovasc Surg 21:172-6. 2009
    ..In this article, we discuss several strategies that involve EPP or pleurectomy/decortication in combination with various adjuvant and neoadjuvant therapies...
  61. ncbi Second-line treatment for malignant pleural mesothelioma
    Giovanni Luca Ceresoli
    Department of Oncology, Istituto Humanitas Gavazzeni, Bergamo, Italy
    Cancer Treat Rev 36:24-32. 2010
    ....
  62. pmc Solitary fibrous tumors of the pleura: results of surgical treatment and long-term prognosis
    Karen M Harrison-Phipps
    Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minn 55905, USA
    J Thorac Cardiovasc Surg 138:19-25. 2009
    ..We sought to define the long-term outcome of surgically treated solitary fibrous tumors of the pleura...
  63. ncbi Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126
    George W Cole
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Anticancer Res 26:809-21. 2006
    ....
  64. ncbi Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia
    Arman Hasani
    Department of Medical Oncology, Sir Charles Gairdner Hospital, Western Australia, Australia
    J Thorac Oncol 4:1010-6. 2009
    ..Thus, TMT was introduced as an option for such patients in Western Australia in 2004. However, TMT has never been compared with non-TMT therapy in the same patient population, thereby introducing a potential for selection bias...
  65. ncbi MESOMARK: a potential test for malignant pleural mesothelioma
    Heather L Beyer
    Research and Development Division, Fujirebio Diagnostics, Inc, Malvern, PA 19355, USA
    Clin Chem 53:666-72. 2007
    ..Soluble mesothelin-related peptides (SMRP)have been reported to be potential biomarkers for malignant pleural mesothelioma (MPM). We report analytical and preliminary clinical studies of MESOMARK, a quantitative assay for SMRP...
  66. ncbi The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline
    Peter Ellis
    McMaster University at Hamilton Health Sciences and Juravinski Cancer Centre, Hamilton, Ontario, Canada
    J Thorac Oncol 1:591-601. 2006
    ....
  67. ncbi Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma
    David C Rice
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:350-7. 2007
    ..To determine the incidence of fatal pulmonary events after extrapleural pneumonectomy and hemithoracic intensity-modulated radiotherapy (IMRT) for malignant pleural mesothelioma...
  68. pmc Phenotypes and karyotypes of human malignant mesothelioma cell lines
    Vandana Relan
    UQ Thoracic Research Centre, School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
    PLoS ONE 8:e58132. 2013
    ..The aim of this study was to develop and biologically characterise six malignant mesothelioma cell lines to evaluate their potential as models of human malignant mesothelioma...
  69. ncbi Ten traps for the unwary in surgical series: a case study in mesothelioma reports
    Tom Treasure
    Department of Cardiothoracic Surgery, Guy s Hospital, London, United Kingdom
    J Thorac Cardiovasc Surg 133:1414-8. 2007
  70. ncbi Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure
    Ottavio Rena
    Thoracic Surgery Unit, Azienda Ospedaliero Universitaria Maggiore della Carita, Novara, Italy
    Lung Cancer 77:151-5. 2012
    ..MPM patients submitted to EPP had a higher post-operative complication rate, a worse long-term QoL, a shorter residual life time after recurrent disease, despite a similar long-term survival when compared to P/D...
  71. ncbi Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma
    Daniel H Sterman
    Thoracic Oncology Research Laboratory, Interventional Pulmonology Program, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 4283, USA
    Respirology 10:266-83. 2005
    ..Over the past decade, significant advances have been made on several fronts that have improved the ability to diagnose a stage, define prognosis, and treat malignant pleural mesothelioma...
  72. ncbi Pemetrexed in malignant pleural mesothelioma
    Maitreyee Hazarika
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, USA
    Clin Cancer Res 11:982-92. 2005
    ..Indianapolis, IN) by the U.S. Food and Drug Administration (FDA) of a New Drug Application for the treatment of malignant pleural mesothelioma (MPM)...
  73. ncbi Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia
    Christopher W Lee
    BC Cancer Agency Fraser Valley Centre, 13750 96th Avenue, Surrey, British Columbia, Canada V3V 1Z2
    Lung Cancer 64:308-13. 2009
    ..No difference is seen combining platinum analogs with gemcitabine or pemetrexed. Platinum-based doublets might represent a therapeutic ceiling for cytotoxic chemotherapy in MPM...
  74. ncbi Caelyx in malignant mesothelioma: a phase II EORTC study
    P Baas
    TheNetherlands Cancer Institute, Amsterdam
    Ann Oncol 11:697-700. 2000
    ..In a phase II study, the efficacy and toxicity of Caelyx was tested in previously untreated patients with malignant pleural mesothelioma...
  75. ncbi Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma
    Claudia Casarsa
    Department of Life Sciences, University of Trieste, Italy
    Cancer Lett 302:136-43. 2011
    ....
  76. ncbi Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma
    Joost P Hegmans
    Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands
    Am J Respir Crit Care Med 181:1383-90. 2010
    ..However, the clinical relevance is still in question. To examine this, we designed a clinical trial using chemotherapy followed by antigen-pulsed dendritic cell vaccination in mesothelioma patients...
  77. pmc Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma
    M Tiainen
    Department of Medical Genetics, University of Helsinki, Finland
    Br J Cancer 60:618-26. 1989
    ..02). In this study no diagnostic cytogenetic markers of mesothelioma were found, instead the copy number of chromosome 7 short arms turned out to be a possible prognostic factor in malignant mesothelioma...
  78. ncbi Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma
    Keith M Skubitz
    University of Minnesota Medical School, Masonic Cancer Center, Minneapolis, MN 55455, USA
    Cancer Invest 20:693-9. 2002
    ..These data suggest that pegylated-liposomal doxorubicin has activity in mesothelioma, and that this treatment is associated with modest toxicity...
  79. ncbi Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis
    Marie Marthe Philippeaux
    Department of Thoracic Surgery, Cantonal Hospital of Geneva University, 1, Rue Micheli du Crest, 1211, 4, Switzerland
    Histochem Cell Biol 122:249-60. 2004
    ..Karyotypic analyses showed more complex abnormalities in the epithelioid subtype than in the sarcomatoid form. These cell lines may be useful in the study of cellular, molecular and genetic aspects of the disease...
  80. pmc Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target
    Stefania Crispi
    Gene Expression Core, Human Molecular Genetics Laboratory, Institute of Genetics and Biophysics, Naples, Italy
    PLoS ONE 4:e7016. 2009
    ....
  81. ncbi Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
    Giovanni L Ceresoli
    Oncology Unit, Cliniche Humanitas Gavazzeni, Bergamo, Italy giovanni
    Lung Cancer 72:73-7. 2011
    ..Further prospective evaluation of this therapeutic option is warranted...
  82. ncbi Solitary fibrous tumors of the pleura: clinical characteristics, surgical treatment and outcome
    Pierre Magdeleinat
    Service de Chirurgie Thoracique, Hotel Dieu, 1, Place du Parvis Notre Dame, 75181 Paris Cedex 04, France
    Eur J Cardiothorac Surg 21:1087-93. 2002
    ..The aim of this paper is to study clinical characteristics, surgical treatment and outcome of patients with solitary fibrous tumor of the pleura operated in our institutions in a 20-year period...
  83. ncbi In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth
    Naohiko Hamaguchi
    Department of Integrated Medicine, Ehime University Graduate School of Medicine, Ehime, Japan
    Cancer Sci 101:1955-64. 2010
    ..These results suggest that TGZ in combination with cisplatin may become a novel therapy for MPM...
  84. ncbi Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts
    James E Littlejohn
    Department of Molecular and Cellular Medicine, Texas A and M Health Science Center, College of Medicine, College Station, TX, USA
    Int J Cancer 123:202-8. 2008
    ..More notably, the combination of Bcl-xL ASO and cisplatin extends survival in an orthotopic tumor xenograft model...
  85. ncbi E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles
    Kenji Ikuta
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
    Clin Cancer Res 15:7229-37. 2009
    ..Therefore, we focused on the multi-tyrosine kinase inhibitor E7080 and assessed its therapeutic efficacy against MPM cells with different proangiogenic cytokine production profiles...
  86. ncbi Pleural mesothelioma in a woman whose documented past exposure to asbestos was from smoking asbestos-containing filtered cigarettes: the comparative value of analytical transmission electron microscopic analysis of lung and lymph-node tissue
    Ronald F Dodson
    Dodson Environmental Consulting, Inc, and ERI Analytical, Tyler, Texas 75701, USA
    Inhal Toxicol 18:679-84. 2006
    ..Combined ATEM data of lung and lymph node tissue clarified the patient's exposure to asbestos and particularly to crocidolite asbestos and thus to the presence of an entity recognized as the causal agent for mesothelioma...
  87. ncbi Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients
    Noriyasu Usami
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 0021, Japan
    Cancer Sci 97:387-94. 2006
    ..Thus, our new MPM cell lines seem to be useful as new models for studying various aspects of the biology of human MPM as well as materials for the development of future therapies...
  88. ncbi Prospective study of mesothelioma mortality in Turkish villages with exposure to fibrous zeolite
    Y Izzettin Baris
    Guven Hospital, Ankara, Turkey
    J Natl Cancer Inst 98:414-7. 2006
    ..Our results emphasize the severity of the mesothelioma endemic in erionite-exposed areas of Turkey and call for intensified prevention of mesothelioma by limiting environmental exposures to these fibers...
  89. ncbi Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
    Minna Tanner
    Laboratory of Cancer Biology, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
    Mol Cancer Ther 3:1585-92. 2004
    ..Erk1/2 phosphorylation was slightly reduced but still evident in JIMT-1 cells. We conclude that the JIMT-1 cell line provides a valuable experimental model for studies of new trastuzumab-resistance mechanisms...
  90. ncbi Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results
    Federico Rea
    Division of Thoracic Surgery, University of Padua, Policlinico di Padova, Italy
    Lung Cancer 57:89-95. 2007
    ..Trimodality therapy results have led us to test induction chemotherapy followed by EPP and adjuvant radiotherapy in stages I-III of MPM. The aim of our study was to evaluate the feasibility of this protocol and to estimate survival...
  91. ncbi Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study
    Tamara R Tilleman
    Department of Thoracic Surgery, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 138:405-11. 2009
    ..We sought to prospectively determine the feasibility and safety of hyperthermic intraoperative intracavitary cisplatin perfusion immediately after extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma...
  92. ncbi Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery
    Myong Cheol Lim
    Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea
    Ann Surg Oncol 16:1990-6. 2009
    ....
  93. ncbi Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study
    Linda L Garland
    University of Arizona Cancer Center, Tucson, AZ, USA
    J Clin Oncol 25:2406-13. 2007
    ..We conducted a phase II trial of the EGFR TKI erlotinib in previously untreated patients with MPM...
  94. ncbi Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register
    Alessandro Marinaccio
    National Institute for Occupational Safety and Prevention ISPESL, Occupational Medicine Department, Epidemiology Unit, Via Alessandria 220 E, 00198 Rome, Italy
    Eur J Cancer 43:2722-8. 2007
    ....
  95. pmc Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
    Haining Yang
    Cancer Research Center of Hawaii, John A Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA
    Proc Natl Acad Sci U S A 107:12611-6. 2010
    ..Chemopreventive approaches aimed at inhibiting the chronic inflammatory response, and especially blocking HMGB1, may decrease the risk of malignant mesothelioma among asbestos-exposed cohorts...
  96. ncbi Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma
    G J Gordon
    The Thoracic Surgery Oncology Laboratory and the Division of Thoracic Surgery, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    J Pathol 211:439-46. 2007
    ....
  97. pmc Malignant mesothelioma
    Alastair J Moore
    Department of Respiratory Medicine, Wexham Park Hospital, Wexham, Slough, Berkshire, UK
    Orphanet J Rare Dis 3:34. 2008
    ..Compensation issues must also be considered. Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis...
  98. pmc Genomic events associated with progression of pleural malignant mesothelioma
    Sergey V Ivanov
    Department of Cardiothoracic Surgery, Thoracic Surgery Laboratory, NYU Langone Medical Center, New York, NY, USA
    Int J Cancer 124:589-99. 2009
    ..2), FUS1 and PL6 (3p21.3), DNAJA1 (9p21.1) and CDH2 (18q11.2-q12.3). Imbalances seen by ROMA were confirmed by Affymetrix genome analysis in a subset of samples...
  99. ncbi Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin
    Paolo Andrea Zucali
    Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Clin Cancer Res 17:2581-90. 2011
    ....
  100. pmc Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype
    Oluf Dimitri Røe
    Department of Oncology, St Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway
    PLoS ONE 4:e6554. 2009
    ..Genome-wide profiling of mesothelioma versus parietal and visceral normal pleural tissue could thus reveal novel genes and pathways explaining its aggressive phenotype...
  101. ncbi Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin
    Diana M Padgett
    Department of Pathology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Am J Surg Pathol 32:123-7. 2008
    ..These findings suggest that cytoplasmic podoplanin expression may be useful in the diagnosis of sarcomatoid mesothelioma, although it should be used with caution on biopsy material...

Research Grants47

  1. Diagnosis and prognosis of lung cancer using gene ratios
    GAVIN GORDON; Fiscal Year: 2004
    ..Specific Aim 4. To develop software for the expression ratio test and to design a form summarizing the results of the diagnostic test kit to clinicians and health care personnel. ..
  2. COMPUTER AIDED DIAGNOSIS IN CT OF THE THORAX
    Samuel Armato; Fiscal Year: 2004
    ....
  3. Standard Database for CT Lung Images
    Samuel Armato; Fiscal Year: 2006
    ..The ideas resented in this proposal are expected to stimulate the efforts of the Consortium toward that goal. ..
  4. Computerized Analysis of Mesothelioma on CT Scans
    Samuel Armato; Fiscal Year: 2009
    ....
  5. CANCER AND LEUKEMIA GROUP B
    David Sugarbaker; Fiscal Year: 2002
    ..Three stages of group development are described: (1) surgeon recruitment phase; (2) patient recruitment phase (educational activities about adjuvant therapy trials. etc.); and (3) protocol development phase (intellectual activities). ..
  6. Gene Ratios for Lung Cancer Detection and Prognosis
    Raphael Bueno; Fiscal Year: 2004
    ..We envision that our methodology will be adaptable to a future clinical scenario where each suspicious nodule would be evaluated by fine needle aspiration determining the diagnosis and best therapeutic options for the patients. ..
  7. Gene Ratio Based Prognosis in Mesothelioma
    Raphael Bueno; Fiscal Year: 2007
    ..We will determine the accuracy of this test in predicting outcome as defined by survival and tumor progression. ..
  8. Role of Cell Mediators in Asbestos-SV40 Carcinogenesis
    Michele Carbone; Fiscal Year: 2009
    ..It is anticipated that the results of the experimens proposed in this application will provide information to design novel preventive and therapeutic approaches for MM. ..
  9. A Decision Aid for Cancer-Surviving Adolescents
    Patricia Hollen; Fiscal Year: 2008
    ..Data will be collected during a semistructured interview for the initial and 12-month clinic visits. Generalized linear models will be used for data analyses. [unreadable] [unreadable] [unreadable]..
  10. SV40 sequences in human tumors: analysis & biologic*
    Michele Carbone; Fiscal Year: 2006
    ....
  11. Molecular Targets for Drug and Radiation Sensitivity
    Stephen Hahn; Fiscal Year: 2007
    ..abstract_text> ..
  12. Photodynamic Therapy for the Treatment of Obstructive E*
    Todd Demmy; Fiscal Year: 2007
    ..This proposal will be instrumental in the development of a novel PDT drug without long-term restrictions of patients' sun exposure. [unreadable] [unreadable]..
  13. PATHOGENESIS OF MESENCHYMAL TUMORS INDUCED BY ASBESTOS
    Agnes Kane; Fiscal Year: 2007
    ..Pharmacologic modulation of persistent inflammation triggered by biopersistent, carcinogenic fibers may provide a new strategy to prevent progression of malignant mesothelioma in exposed populations. ..
  14. GENERAL CLINICAL RESEARCH CENTER
    Karen Antman; Fiscal Year: 2008
    ..abstract_text> ..
  15. Role of Fra-1 in Mesothelioma
    Maria Ramos Nino; Fiscal Year: 2008
    ..The long-term goal of this research plan is to understand the molecular mechanisms governing mesothelial cell tumorigenesis. ..
  16. Chemical, Structural, and Superstructural Determinants of Nanocarbon Toxicity
    Agnes B Kane; Fiscal Year: 2010
    ..Identification of specific chemical and physical properties of nanomaterials responsible for cellular toxicity will enable development of manufacturing methods and post processing steps to eliminate intrinsic toxicity. ..
  17. REPLICATIVE ADENOVIRUSES WITH ENHANCED INFECTIVITY
    David Curiel; Fiscal Year: 2008
    ..As well, proof-of principle studies in model systems will establish the rationale for an advanced human clinical trial for cancer of the ovary with derived advanced generation CRAd agents. ..
  18. CANCER GENE THERAPY TRAINING PROGRAM
    David Curiel; Fiscal Year: 2008
    ..The university also has modern animal facilities supervised by veterinarians and run by trained animal care personnel working under NIH guidelines. ..
  19. Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach
    David Curiel; Fiscal Year: 2008
    ..This project will design new and innovative methodologies to create HIV vaccines, in hopes of preventing the spread of HIV disease. ..
  20. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
    ..This work is anticipated to enhance our understanding of KS pathogenesis, provide opportunities for novel therapies for KS, and contribute to the understanding of vascular biology. ..
  21. Insulin-like growth factor axis influence on HIV and HPV pathogenesis in women
    Howard Strickler; Fiscal Year: 2008
    ..abstract_text> ..
  22. Development of double-targeted vectors for long-term vascular expression in vivo
    DAVID TERRY CURIEL; Fiscal Year: 2010
    ..In this proposal, we seek to engineer a safer, less immunogenic Ad vector capable of long-term gene expression. ..
  23. HOST RESPONSE TO TB AND AIDS
    William Rom; Fiscal Year: 2006
    ..This study is critical in developing efficacious treatment strategies for TB and demonstrating that rIFN-gamma ameliorates the lung fibrosis and destruction in advanced TB. ..
  24. Natural Killer Dendritic Cells in Cancer
    BRYAN BURT; Fiscal Year: 2007
    ..We anticipate that our findings will elucidate how this novel cell type may contribute to a variety of immune processes and how NKDC may be useful in the treatment of cancer. [unreadable] [unreadable] [unreadable] [unreadable]..
  25. ASPL TFE3 fusion in human cancers
    Marc Ladanyi; Fiscal Year: 2006
    ..3->qter; and finally analyze selected candidate genes in the same region for inactivating mutations. ..
  26. SCANNING ELECTRON MICROSCOPY SYSTEM
    John Godleski; Fiscal Year: 2001
    ..Institutional support is demonstrated by past support of the facility, completed renovations, commitments for ongoing service contracts, and letters of commitment for future support. ..
  27. ADENOVIRAL MEDIATED TARGETED GENE DELIVERY
    David Curiel; Fiscal Year: 2001
    ..The derivation of this 'targetable injectable' vector system would represent a potentially powerful technical advance allowing the implementation of a variety of strategies to accomplish gene therapy for cancer. ..
  28. Clinical Trials of FTI Radiosensitization
    Stephen Hahn; Fiscal Year: 2005
    ..Specific molecular markers that are associated with activation of the Ras signaling pathway will be measured in NSCLC tumor biopsy specimens and will be related to the clinical efficacy of R115777 and radiotherapy. ..
  29. IMMUNE RESPONSE IN THE LUNG TO TB PROTEINS IN AIDS
    William Rom; Fiscal Year: 2002
    ..tb. proteins in PBMCs and BAL. This proposal will provide critical information on memory immunity in the lung when humans are infected/exposed to M. tb. and how this "protective" immune response to TB may be perturbated in AIDS. ..
  30. REPLICATIVE ADENOVIRUSES WITH ENHANCED INFECTIVITY
    David Curiel; Fiscal Year: 2003
    ..Finally, we intend to demonstrate the oncolytic efficacy of these enhanced-infectability tumor- selective adenoviruses in murine models. ..
  31. Insulin and IGF In female colon, breast, uterine cancer
    Howard Strickler; Fiscal Year: 2005
    ....
  32. Cardiac vulnerability due to ambient particulate
    John Godleski; Fiscal Year: 2008
    ..Thus, the present application will entail unique application of comprehensive techniques to improve understanding of the mechanisms whereby CAPs can exert its deleterious influences on the heart and circulation [unreadable] [unreadable]..
  33. Endothelial Gene Delivery for Pulmonary Hypertension
    David Curiel; Fiscal Year: 2004
    ..abstract_text> ..
  34. DENDRITIC CELL SPECIFIC VECTOR
    David Curiel; Fiscal Year: 2004
    ..Ultimately, advances made during this study will help in translating the current knowledge into clinical practice for the treatment of cancer by inducing a tumor-specific immune response. ..
  35. HPV ETIOLOGY OF A SUBSET OF HEAD AND NECK CANCERS
    Keerti Shah; Fiscal Year: 2004
    ..If HPV etiology is established for a subset of HNSCC, patients with these tumors may benefit from HPV-specific immunotherapies which are being evaluated for the treatment of invasive cervical cancer. ..
  36. Capsid-labeled adenovirus for virotherapy monitoring
    David Curiel; Fiscal Year: 2009
    ..Not only would this system be indispensable in developing advanced CRAds, it would also be applicable for monitoring CRAd therapy in patients. ..
  37. Effects of HLA and KIR genotype on HIV and HCV
    Howard Strickler; Fiscal Year: 2006
    ..WlHS is a large, racially and geographically diverse cohort of HIV(+) (n=2761 with - 40% HCV(+)), and HIV(-) women who share similar risk factors (n=942 with - 25%HCV(+)). ..
  38. New York University School of Medicine CTSA Planning Grant
    William Rom; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  39. OCCUPATIONAL INJURIES AMONG COMMERCIAL FISHERS
    Dana Loomis; Fiscal Year: 2003
    ..abstract_text> ..
  40. CHRYSOTILE AND LUNG CANCER: TIME-RELATED EFFECTS AND POOLED ANALYSIS
    Dana Loomis; Fiscal Year: 2009
    ....
  41. BIOMATHEMATICAL APPROACHES TO CANCER
    Suresh Moolgavkar; Fiscal Year: 2005
    ..The results of analyses will be used to help generate biologically relevant questions and hypotheses and to plan further experiments and studies, which, in turn, will lead to more refined models. ..
  42. Regulation of Lung Epithelial Fibrinolysis by Urokinase
    Sreerama Shetty; Fiscal Year: 2005
    ..This information could hasten the development of new, mechanism-based interventions for lung disorders, including acute lung injury or lung neoplasia. ..
  43. OCCUPATIONAL FATALITY TRENDS: A CONTEXTUAL ANALYSIS
    Dana Loomis; Fiscal Year: 2002
    ..abstract_text> ..
  44. CONTROL OF FIBRINOLYTIC PATHWAYS IN LUNG DISEASE
    Sreerama Shetty; Fiscal Year: 2004
    ..abstract_text> ..
  45. Stochastic models for radiation carcinogenesis: tempora*
    Suresh Moolgavkar; Fiscal Year: 2004
    ..The main goals of these analyses are to explore the effects of various age- and time-related factors and of protraction of exposure on the risk of radiation carcinogenesis. ..
  46. UNIQUE TISSUE AND TUMOR PROCESSING FACILITY
    Adi Gazdar; Fiscal Year: 2003
    ..A charge back fee system will recover some of the costs and will be used for future expansion of the Facility, which is anticipated to become self sustaining after five years. ..
  47. RESTORATION OF APOPTOSIS IN CANCER
    Jack Roth; Fiscal Year: 2003
    ..The studies included in the Program Project could lead to cancer treatments targeted to specific genetic lesions in the cancer cell, thus representing novel mechanisms of action that could complement existing therapies. ..